sub:assertion {
sub:assertion prov:wasGeneratedBy "S&T TWOC project version 1" .
sub:version prov:value 1 .
rdf:object ns1:C0205210 "clinical" ;
ns1:C0332281 "associated" ;
ns1:C0877248 "adverse events" ;
ns1:C1705413 "adverse events" ;
ns1:C3272565 "clinical" .
rdf:predicate ns3:TRIPLE_UID:a5s1weub-TRIPLE-ABSTRACT-3 "remain" .
rdf:subject ns1:C0001617 "corticosteroids" ;
ns1:C0003232 "antibiotics" ;
ns1:C0003237 "antibiotics" ;
ns1:C0003404 "antiparasitics" ;
ns1:C0005515 "biologics" ;
ns1:C0008269 "chloroquine" ;
ns1:C0011777 "dexamethasone" ;
ns1:C0013227 "drugs" ;
ns1:C0020336 "hydroxychloroquine" ;
ns1:C0035366 "retroviral" ;
ns1:C0052796 "azithromycin" ;
ns1:C0087111 "therapeutic" ;
ns1:C0181496 "label" ;
ns1:C0205195 "combination" ;
ns1:C0205423 "certain" ;
ns1:C0292818 "ritonavir" ;
ns1:C0674432 "lopinavir" ;
ns1:C0723712 "therapeutic" ;
ns1:C0812732 "azithromycin" ;
ns1:C1138226 "favipiravir" ;
ns1:C1522485 "label" ;
ns1:C1547427 "therapeutic" ;
ns1:C1609165 "tocilizumab" ;
ns1:C1704787 "certain" ;
ns1:C1705425 "label" ;
ns1:C1708698 "led" ;
ns1:C1947911 "combination" ;
ns1:C1947944 "use" ;
ns1:C2827499 "label" ;
ns1:C3245505 "potential" ;
ns1:C3470573 "led" ;
ns1:C3539185 "corticosteroids" ;
ns1:C3540704 "antibiotics" ;
ns1:C3540705 "antibiotics" ;
ns1:C3540706 "antibiotics" ;
ns1:C3540707 "antibiotics" ;
ns1:C3540708 "antibiotics" ;
ns1:C3540709 "antibiotics" ;
ns1:C3540710 "antibiotics" ;
ns1:C3540725 "corticosteroids" ;
ns1:C3540726 "corticosteroids" ;
ns1:C3540727 "corticosteroids" ;
ns1:C3687832 "drugs" ;
ns1:C3811910 "combination" ;
ns1:C4522130 "label" ;
ns1:C4551445 "label" ;
ns1:C4553887 "biologics" ;
ns1:C4726677 "remdesivir" ;
ns1:C5203670 "COVID-19" .
rdfs:Triple-UID ns2:TRIPLE_UID:a5s1weub-TRIPLE-ABSTRACT-3 "a5s1weub-TRIPLE-ABSTRACT-3" .
rdfs:sentence rdfs:label "Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs's off-label use against COVID-19, such as anti-retroviral drugs (remdesivir, favipiravir, and lopinavir-ritonavir combination), biologics (tocilizumab), antibiotics (azithromycin), antiparasitics (chloroquine and hydroxychloroquine), and corticosteroids (dexamethasone), unfortunately, the associated clinical neuropsychiatric adverse events remains a critical issue." .
rdfs:triple rdfs:label "Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs 's off - label use against COVID-19 , such as anti - retroviral drugs ( remdesivir , favipiravir , and lopinavir - ritonavir combination ) , biologics ( tocilizumab ) , antibiotics ( azithromycin ) , antiparasitics ( chloroquine and hydroxychloroquine ) , and corticosteroids ( dexamethasone ) remains the associated clinical neuropsychiatric adverse events" .
}